thymosin alpha 1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-22. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
=== Technical limitations === When the patient's body has insufficient adipocyte tissue to harvest as injectable breast filler, a combination of fat grafting and breast implants might provide the desired outcome. Although non-surgical breast augmentation with fat graft injections is not associated with implant-related medical complications (filler leakage, deflation, visibility, palpability, capsular contracture), the achievable breast volumes are physically limited; the large-volume, global bust augmentations realised with breast implants are not possible with the method of structural fat grafting. Global breast augmentation contrasts with the controlled breast augmentation of fat-graft injection, in the degree of control that the plastic surgeon has in achieving the desired breast contour and volume. The controlled augmentation is realised by infiltrating and diffusing the fat grafts throughout the breast; and it is feather-layered into the adjacent pectoral areas until achieving the desired outcome of breast volume and contour. Nonetheless, the physical fullness-of-breast achieved with injected fat-grafts does not visually translate into the type of buxom fullness achieved with breast implants; hence, patients who had plentiful fat-tissue to harvest attained a maximum breast augmentation of one bra cup size in one session of fat grafting to the breast.
He also notes a venom yield of 200–411 mg. Human envenoming by this species, although infrequent, can be rather severe due to the large volumes of venom injected. Envenomation is characterized by pronounced local tissue damage and systemic dysfunctions, including massive internal bleeding.
=== Southern expansion === In January 2020, Governor Andrew Cuomo unveiled a proposed southern annex to Penn Station, part of his vision for the Empire Station Complex. The annex would include eight new tracks with four platforms and would involve demolishing the entire block bounded by 30th and 31st streets between Seventh and Eighth avenues, directly south of the existing station, as well as parts of the two blocks to the east and west. The new tracks would connect to and take advantage of the new capacity provided by the Hudson River tunnels built as part of the Gateway Program. The necessity of new tracks has been debated by regional advocacy groups who suggest that service improvements to enable regional through-running could similarly boost capacity. The southern terminal, which could cost as much as $16.7 billion, never proceeded; in March 2025 Governor Kathy Hochul said she no longer supported demolition of the block, and in August 2025 Amtrak said it was abandoning the expansion in favor of reconstructing the existing station and exploring other capacity improvements such as through-running.
Danyelle M. Townsend is a biomedical scientist, and academic. She is a Professor and acting Department Chair of Drug Discovery and Biomedical Sciences at the Medical University of South Carolina (MUSC). Townsend's lab utilizes proteomics and analytical biochemistry to identify molecular targets affected by oxidative and nitrosative stress, exploring the impact of redox signaling on cellular responses. Her research on the redox proteome and associated pathways has contributed to drug discovery and redox biomarker development. Townsend has authored over 150 peer-reviewed publications including journal articles, book chapters, and co-edited a book titled, Redox and Cancer Part A. In addition, she served as Co-Editor for Biomedicine and Pharmacotherapy from 2014 to 2015, and has been the Editor-in-Chief for this journal since 2015.
The hydrogen bond criterion for beta turns, applied to polypeptides whose amino acids are linked by trans peptide bonds, gives rise to just four categories, as shown by Venkatachalam in 1968. They are called types I, II, I' and II'. All occur regularly in proteins and polypeptides but type I is most common, because it most resembles an alpha helix, occurring within 310 helices and at the ends of some classic alpha helices. Type II beta turns, on the other hand, often occur in association with beta-sheet as part of beta-links. The four types of beta turn are distinguished by the φ, ψ angles of residues i+1 and i+2 as shown in the table below giving the typical average values. Glycines are especially common as amino acids with positive φ angles; for prolines such a conformation is sterically impossible but they occur frequently at amino acid positions where φ is negative.
Sources: en.wikipedia.org
== Side effects == Drinking alcohol while taking tinidazole causes an unpleasant disulfiram-like reaction, which includes nausea, vomiting, headache, increased blood pressure, flushing, and shortness of breath.
Note that most commonly used lac or lac-derived promoters are based on the lacUV5 mutant which is insensitive to catabolite repression. This mutant allows for expression of protein under the control of the lac promoter when the growth medium contains glucose since glucose would inhibit gene expression if wild-type lac promoter is used. Presence of glucose nevertheless may still be used to reduce background expression through residual inhibition in some systems. Examples of E. coli expression vectors are the pGEX series of vectors where glutathione S-transferase is used as a fusion partner and gene expression is under the control of the tac promoter, and the pET series of vectors which uses a T7 promoter. It is possible to simultaneously express two or more different proteins in E. coli using different plasmids. However, when 2 or more plasmids are used, each plasmid needs to use a different antibiotic selection as well as a different origin of replication, otherwise one of the plasmids may not be stably maintained. Many commonly used plasmids are based on the ColE1 replicon and are therefore incompatible with each other; in order for a ColE1-based plasmid to coexist with another in the same cell, the other would need to be of a different replicon, e.g. a p15A replicon-based plasmid such as the pACYC series of plasmids. Another approach would be to use a single two-cistron vector or design the coding sequences in tandem as a bi- or poly-cistronic construct.
== Reactions == Superheated water, along with supercritical water, has been used to oxidise hazardous material in the wet oxidation process. Organic compounds are rapidly oxidised without the production of toxic materials sometimes produced by combustion. However, when the oxygen levels are lower, organic compounds can be quite stable in superheated water. As the concentration of hydronium (H3O+) and hydroxide (OH−) ions are 100 times larger than in water at 25 °C, superheated water can act as a stronger acid and a stronger base, and many different types of reaction can be carried out. An example of a selective reaction is oxidation of ethylbenzene to acetophenone, with no evidence of formation of phenylethanoic acid, or of pyrolysis products. Several different types of reaction in which water was behaving as reactant, catalyst and solvent were described by Katritzky et al. Triglycerides can be hydrolysed to free fatty acids and glycerol by superheated water at 275 °C, which can be the first in a two-stage process to make biodiesel.
== P == p53 - package - palindromic sequence - palmitoyl acyltransferase - Parkinson's disease - Partial cleavage stimulation factor domain - pBR322 - PCR - pedigree - peptide - peptide-transporting ATPase - peptide bond - phage - phagemid - phenotype - phenylacetaldoxime dehydratase - PhIP-Seq - phosphatase, alkaline - phosphatidylcholine 12-monooxygenase - phosphatidylcholine desaturase - phosphatidylinositol a-mannosyltransferase - phosphodiester bond - phospholipid acyltransferase - phosphonate-transporting ATPase - phosphorylation - physical map - plant calmodulin-binding domain - plasmid - plastoquinol/plastocyanin reductase - point mutation - poly-A track - polyA tail - polyacrylamide gel - polyclonal antibodies - polydactyly - polymerase - polymerase chain reaction - polymorphism - polynucleotide kinase - polypeptide - polyvinyl-alcohol dehydrogenase (acceptor) - positional cloning - positional sequencing - post-transcriptional regulation - post-translational modification - post-translational processing - post-translational regulation - PRE - precursor mRNA - primary immunodeficiency - primary transcript - primer - primer extension - probe - processivity - progesterone 5alpha-reductase - promoter - pronucleus - prostate cancer - protease - proteasome - proteasome ATPase - protein - Protein translocation - proto-oncogene - pseudobaptigenin synthase - pseudogene - pseudoknot - pseudorevertant - pulse sequence database - pulsed field gel electrophoresis - purine - PyrC leader - PyrD leader - pyrimidine
Sources: en.wikipedia.org
=== Disadvantages === Reduced immunogenicity compared to attenuated vaccines Require adjuvants to improve immunogenicity Often require multiple doses ("booster" doses) to provide long-term immunity Can be difficult to isolate the specific antigen(s) which will invoke the necessary immune response It is not easy to supervise conjugation chemistry which leads to noncontinuous variation
Healthcare in Romania is mainly provided by the public sector, which runs most hospitals and offers national health insurance to nearly all citizens. In 2021, healthcare costs were US$16. 7 billion, or US$2,385 per person, making up €5.69 of GDP. Government spending is higher than in markets like Bulgaria but lower than Hungary. Spending is expected to rise by 7. US$5 billion (+37. 68%) from 2024 to 2028, reaching 27. US$3 billion by 2028. The Romanian National Institute of Statistics reports over 65,000 health units in Romania, with 53,000 in urban areas and 12,000 in rural areas. There are 543 hospitals, including 488 in urban and 55 in rural areas, along with 160 other hospital-like establishments. Nearly 50% of these are large facilities with over 100 beds, while 39% are small with fewer than 50 beds. The total number of inpatient beds is 135,085, allocated mainly to psychiatry, surgery, and internal medicine among other specialties.
The Cossacks of Zaporizhzhia, centered on the lower bends of the Dnieper, in the territory of modern Ukraine, with the fortified capital of Zaporozhian Sich. They were given significant autonomous privileges, operating as an autonomous state (the Zaporozhian Host) within the Polish-Lithuanian Commonwealth, by a treaty with Poland in 1649. The Don Cossack State, on the River Don. Its capital was initially Razdory, then it was moved to Cherkassk, and later to Novocherkassk. There are also references to less well-known Tatar Cossacks, including the Nağaybäklär and Meshchera-speaking Volga Finns, of whom Sary Azman was the first Don ataman. It is a strange, conflicting report that these groups were assimilated by the Don Cossacks since the Turks were Muslim, the Cossack Orthodox Christian. It could be the assimilation took place in the event of raiding opposing tribes and the taking of slaves. Some are reported to have had their own irregular Bashkir and Meshchera Host up to the end of the 19th century. The Kalmyk and Buryat Cossacks also deserve mention.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.